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Abstract
Pathogenic variants in the ATP‐binding cassette transporter A4 (ABCA4) gene cause a
continuum of retinal disease phenotypes, including Stargardt disease. Noncanonical
splice site (NCSS) and deep‐intronic variants constitute a large fraction of disease‐
causing alleles, defining the functional consequences of which remains a challenge.
We aimed to determine the effect on splicing of nine previously reported or
unpublished NCSS variants, one near exon splice variant and nine deep‐intronic
variants in ABCA4, using in vitro splice assays in human embryonic kidney 293T cells.
Reverse transcription‐polymerase chain reaction and Sanger sequence analysis
revealed splicing defects for 12 out of 19 variants. Four deep‐intronic variants
create pseudoexons or elongate the upstream exon. Furthermore, eight NCSS
variants cause a partial deletion or skipping of one or more exons in messenger RNAs.
Among the 12 variants, nine lead to premature stop codons and predicted truncated
ABCA4 proteins. At least two deep‐intronic variants affect splice enhancer and
silencer motifs and, therefore, these conserved sequences should be carefully
evaluated when predicting the outcome of NCSS and deep‐intronic variants.
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1 | INTRODUCTION
Inherited retinal diseases (IRDs) are clinically and genetically
heterogeneous conditions (Berger, Kloeckener‐Gruissem, & Neid-
hardt, 2010; Sullivan & Daiger, 1996), which makes it a great
challenge for clinicians to come to a genetic diagnosis in affected
individuals. However, by defining the genetic cause, the genetic risk
of the disease for other family members can be assessed and it
provides essential prognostic information for affected family
members and possible therapeutic approaches. More knowledge of
genetic variability in a gene will also provide better insight and
understanding of the disease mechanism (Carss et al., 2017;
Ellingford et al., 2015).
The rise of next‐generation sequencing technology has drastically
changed the opportunities in obtaining a genetic diagnosis in affected
individuals (Neveling et al., 2012; Vaz‐Drago, Custódio, & Carmo‐
Fonseca, 2017). Using these techniques, hundreds of thousands of
single‐nucleotide (nt) variants are detected in each individual.
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However, in many instances, the functional significance of variants
remains unclear. Several in silico tools predict the putative effect of
missense and splice variants. The latter variants can be experimen-
tally assessed for their pathogenicity by performing in vitro midigene
splice assays (Sangermano et al., 2018).
Stargardt disease 1 (STGD1; MIM# 600110) is the most common
inherited macular disease. It is characterized by bilateral progressive
loss of central vision, color vision defect, photophobia, and
importantly, delayed dark adaptation and fundus imaging point to
accumulation of lipofuscin (Fishman, Farbman, & Alexander, 1991;
Stargardt, 1909). STGD1 is an autosomal recessive disease caused by
pathogenic variants in the ATP‐binding cassette subfamily A member
4 (ABCA4) gene (MIM# 601691; NM_000350.2; Allikmets et al.,
1997). The protein is comprised of two tandem halves, each of which
consists of a nt‐binding domain, a cytoplasmic domain, and a
transmembrane domain, followed by a large extracellular segment
(Bungert, Molday, & Molday, 2001). ABCA4 is a 128 kb gene
containing 50 exons that encodes a polypeptide of 2,273 amino
acids and is located in the rod and cone photoreceptor cells, as well
as the retinal pigment epithelium (Ahn, Wong, & Molday, 2000; Lenis
et al., 2018; Sun, Molday, & Nathans, 1999). One or both copies of
this gene were found to be mutated in the majority of patients with
STGD1 (Zernant et al., 2014), in 30% of patients with cone‐rod
dystrophy (Cremers et al., 1998; Maugeri et al., 2000), and in
approximately 5% of individuals with pan‐retinal dystrophy or a
phenotype resembling retinitis pigmentosa (Cremers et al., 1998).
The ABCA4 gene carries many pathogenic noncanonical splice site
(NCSS) variants. A comprehensive study on all ABCA4 variants
published up to 2016 showed a total of 5,962 likely causal variants or
alleles in ABCA4 of which 13.6% (809/5,962) are located in NCSS
(Cornelis et al., 2017). These NCSS variants are located at the first
and last three nucleotides of an exon as well as the −3 to −14nts from
the acceptor site, and +3 to +6 from the donor site. Besides NCSS
variants, many pathogenic variants were observed in canonical
sequences at the AG‐acceptor (−1 and −2) and GT‐donor (+1 and
+2) nucleotides. The functional consequences of many NCSS variants
in ABCA4 were revealed using in vitro minigene and midigene splice
assays in human embryonic kidney 293T (HEK293T) cells (Sanger-
mano et al., 2018; Schulz et al., 2017).
Until recently, a single pathogenic variant was identified in
approximately 25% of STGD1 cases worldwide (Zernant et al., 2014,
2017). Approximately 40% of these cases (~10% of all STGD1 cases),
many of whom showing late‐onset STGD1, were explained by the
frequent coding variant c.5603A>T (p.Asn1868Ile) with an allele
frequency of 0.07 in most control populations. This variant generally
was found in trans with severe ABCA4 variants (Runhart et al., 2018;
Zernant et al., 2017). Another 40% of monoallelic STGD1 probands
(10% of all STGD1 cases) carried deep‐intronic variants in their
second alleles (Bauwens et al., 2019; Braun et al., 2013; Sangermano
et al., 2019; Zernant et al., 2014). The functional consequences of
many of these variants only came to light when performing in vitro
splice assays (Bauwens et al., 2019; Sangermano et al., 2019) or by
reverse transcription‐polymerase chain reaction (RT‐PCR) analysis of
photoreceptor progenitor cells differentiated from patient‐derived
induced pluripotent stem cells (Albert et al., 2018; Sangermano et al.,
2016).
F IGURE 1 Schematic representation of
mutant midigene splice constructs of
ABCA4 and corresponding locations of the
NCSS and deep‐intronic variants tested.
The exons are represented as black
rectangles. BA depicts the BAC‐derived
clones used that were previously described
(Sangermano et al., 2018). The BA11 and
BA15 variants each were introduced
separately into the WT constructs. ABCA4,
ATP‐binding cassette subfamily A member
4; BAC, bacterial artificial chromosome;
NCSS, noncanonical splice site; WT,
wild‐type
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To expand the knowledge of the consequences of NCSS and deep‐
intronic variants in ABCA4, we studied reported and unpublished NCSS,
as well as reported deep‐intronic variants in ABCA4 employing midigene‐
based splice assays. This study contributes to a deeper understanding of
alternative splicing through the activation of cryptic splice sites and the
presence of exonic splice enhancers (ESEs) or exonic splice silencers
(ESSs) and provides evidence for the pathogenicity of 12 splicing variants,
thereby significantly expanding our knowledge of the effects of putative
splice defects.
2 | MATERIALS AND METHODS
2.1 | Editorial policies and ethical considerations
The study adhered to the tenets of the Declaration of Helsinki and
was approved by the local ethics committees of each participating
center. Written informed consent was obtained from patients before
inclusion in the study.
2.2 | Clinical studies
The 12 probands carried pathogenic ABCA4 variants (Table S1)
and were diagnosed with macular dystrophies or cone‐rod
dystrophy (Tables S2 and S3). Medical records of each patient
were reviewed for clinical examination including the age of onset,
visual acuity, fundus photography, and electroretinogram, where
available.
2.3 | Selection of NCSS and deep‐intronic ABCA4
variants
Variants were selected for in vitro analysis when they adhered to the
following criteria: (a) NCSS and “near exon aberrant RNA” (NEAR) splice
variants were predicted to result in a reduction of at least 2% of the
relative strength in at least two of five different splice site prediction
algorithms i.e. Splice Site Finder‐like (SSFL), MaxEntScan, NNSPLICE,
GeneSplicer, and human splicing finder (HSF) (Desmet et al., 2009; Pertea
et al., 2001; Reese et al., 1997; Shapiro & Senapathy, 1987; Yeo & Burge,
2004). Moreover, variants were selected when nearby (up to 300 base
pairs [bps]) a cryptic splice site was strengthened or created.
Deep‐intronic variants were included if a mutant cryptic
splice site was predicted by at least two out of five algorithms
with ≥75% score in the presence of an already existing other
splice site within 300 nts, which together could result in the
formation of a pseudoexon (PE) (Sangermano et al., 2019). As it
has been shown that ESEs and ESSs have a significant effect on
the splicing process in human cells we assessed ESEs through
ESEfinder, an in silico prediction tool integrated with Alamut®
version 2.10 (Cartegni, Chew, & Krainer, 2002; Fairbrother &
Chasin, 2000). ESEfinder determines the presence of five
different ESE elements, that is SF2/ASF, SF2/ASF (immunoglo-
bulin M‐BRCA1), SC35, SRp40, and SRp55 (Cartegni, Wang, Zhu,
Zhang, & Krainer, 2003; Smith et al., 2006). Moreover, suggested
pathogenic variants adhered to the selection criteria when
differences could be observed in predicted ESEs or ESSs between
wild‐type (WT) and mutant sequences. ESSs were assessed
through algorithms incorporated in HSF as introduced by Wang
et al. (2004) and Sironi et al. (2004).
Nineteen variants were selected to be assessed by a
midigene splice assays. All in silico splice site prediction
scores of the variants investigated in this study are provided in
Table S4. Of these, 16 variants were previously reported
(Bauwens et al., 2019; Cornelis et al., 2017; Fujinami et al.,
2013; Tayebi et al., 2019; Zernant et al., 2014, 2017; Zhang,
Arias, Ke, & Chasin, 2009), we also assessed in‐house data based
on molecular inversion probes‐based sequence analysis of 108
TABLE 1 In vitro assessed NCSS variants and the observed RNA and predicted protein effects
DNA variant RNA effect Protein effect Splice defect
Variant
effect
c.161G>A r.[161_302del,=]b p.[Cys54Serfs*14,Cys54Tyr] Exon 3 skipping Moderatea
c.1937+5G>A r.1806_1937del p.(Tyr603_Ser646del) 132‐nt exon 13 deletion Severe
c.2161−8G>A r.2161_2382del p.(His721_Val794) Exon 15 skipping Severe
c.3608−7G>A r.= p.(=) None N.A.
c.4667G>A r.4635_4667del p.(Ser1545_Gln1555del) Exon 32 skipping Severe
c.5018+5G>A r.4849_5018del p.(Val1617Alafs*113) Exon 35 skipping Severe
c.5715−5T>G r.5461_5714delins5715-
4_5715-1
p.(Thr1821Serfs*34) Exon 39/40 skipping Severe
c.6147G>A r.6006_6147del p.(Ser2002Argfs*11) Exon 44 skipping Severe
c.6385A>G r.6340_6386del p.(Val2114Hisfs*4) 47‐nt exon 46 deletion Severe
Note: The RNA and protein effect annotations show the most abundant product followed by the less abundant RNA product observed.
Abbreviations: N.A., not applicable; NCSS, noncanonical splice site.
aThe splice defect is classified as moderate. However, the missense variant Cys54Tyr was proposed earlier to be considered a severe variant in Stargardt
cases.
bThe equal sign depicts the presence of >15% WT RNAs.
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F IGURE 2 Overview of splice defects for nine NCSS variants. Exon 5 RHO RT‐PCR was used as a control for transfection efficiency.
The chromatogram presents the nucleotides identified in the mutant midigene construct. (a) Exon 3 showed weak natural exon skipping
in the WT construct, which is significantly increased for the c.161G>A mutant. (b) The recruitment of a cryptic SDS in exon 13 at
position c.1806 resulted in a 132‐nt deletion. (c) The c.2161−8G>A mutant construct showed full exon 15 skipping. Note that exon 15
also shows natural exon skipping. (d) c.3608−7G>A did not result in a splice defect. (e, f) Variants c.4667G>A and c.5018+5G>A led to
complete exon 32 and 35 skipping, respectively. (g) RT‐PCR for the c.5715−5T>G mutant construct showed a complex splicing pattern.
Exons 39 and 40 are partially skipped in the WT messenger RNA (mRNA); c.5715−5T>G induced exon 39/40 skipping. This variant also
created a new splice acceptor site (SAS) upstream of exon 41 which led to the insertion of four nucleotides into the mature mRNA. (h)
c.6147G>A caused complete exon 44 skipping. (i) The use of a cryptic SDS in exon 46 caused the 47‐nt exon deletion. bp, base pair;
HSF, human splicing finder; int, intron; NCSS, noncanonical splice site; nt, nucleotide; RT‐PCR, reverse transcription‐polymerase chain
reaction; SDS, splice donor site; WT, wild‐type
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inherited retina‐disease associated genes in an approximately
5,000 probands (S. R. and F. P. M. C., unpublished data). The
latter analysis led to the inclusion of c.1937+5G>A,
c.5715−5T>G, and c.6147G>A, as these fulfilled the criteria
described above.
2.4 | Generation of ABCA4 WT and mutant
midigenes
Previously, we generated a library of 31 overlapping WT midigenes
(BA1–BA31; Sangermano et al., 2018) (Khan et al., 2019). Through
Gateway cloning and subsequent site‐directed mutagenesis, mutant
F IGURE 2 Continued
FADAIE ET AL. | 2369
constructs were generated for all 19 variants investigated in this study
(Figure 1). Subsequently, WT and mutant constructs were independently
transfected in HEK293T cells, assessed through RT‐PCR, gel analysis, and
followed by Sanger sequencing of the observed fragments. When a
multitude of products was observed after gel electrophoresis, they were
quantified using Fiji software, as previously described (Sangermano et al.,
2018). In addition, for the c.5715−5T>G variant, all observed fragments
were cloned via the pGEM‐T Easy Vector System I (Promega, Madison,
WI) according to the manufacturer’s protocol and analyzed by Sanger
sequencing. All mutagenesis, exonic primers, and quantificationmeasure-
ments are available in Tables S5–S7.
3 | RESULTS
3.1 | Splicing effect of NCSS variants in ABCA4
The nine NCSS variants experimentally assessed with their observed
effect on splicing are listed in Table 1. Of all variants, only two were
FIGURE 3 Continued.
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observed in the “control” population database gnomAD (c.161G>A,
allele frequency: 0.00003608; c.3608−7G>A, allele frequency:
0.000004087). Four of the selected variants (c.161G>A,
c.4667G>A, c.6147G>A, and c.6385A>G) were in the coding regions
of ABCA4, whereas the remaining NCSS variants were located in
introns. Eight of the nine NCSS variants led to partial or entire exon
skipping, while only c.3608−7G>A did not show an effect on splicing.
The c.1937+5G>A, c.2161−8G>A, and c.4667G>A variants led to
partial in‐frame deletions of ABCA4 exons. The c.6385A>G variant
caused an open reading frame disruption by a 47‐nt deletion of exon
46 due to the use of a cryptic splice donor site (SDS) at position
c.6340 in the exon (Figure 2). The other five NCSS variants caused
frameshifts and led to predicted truncated proteins (Table 1).
Variant c.5715−5T>G, located five nucleotides upstream of exon
41, showed a complex defect in splicing compared with the WT
product. Among the different fragments, we observed exon 39
skipping as well as exon 39/40 skipping. The most prominent mutant
messenger RNA (mRNA) contained a 4‐nt insertion of the exon 41
splice acceptor site (SAS) along with exon 39/40 skipping. We did not
observe any mRNA with only exon 40 skipping.
3.2 | Splicing effect of deep‐intronic variants
The 10 NEAR and deep‐intronic variants with their observed effect
on splicing from this study are presented in Table 2. None of these
variants was observed in gnomAD, indicating that they are very rare.
Four showed a splicing defect, while the other six variants did not
show any effect on splicing (Figure S1). Of the four variants that
did show a splice defect, c.1938−619A>G, c.2919−826T>A, and
c.3050+370C>T created a PE in the mature mRNAs, leading to a
frameshift and a subsequent predicted truncated protein. The NEAR
splicing variant c.4352+61G>A elongated the ABCA4 mRNA down-
stream of exon 29 by 57 nts, resulting in a premature stop codon,
likely due to an increased cryptic SDS score according to five
prediction algorithms, even though there is an inactivation of several
ESE protein binding motifs, such as SC35 and SF2/ASF (Figure 3).
Of the six variants that showed no effect on splicing, the
c.768+358C>T, c.769−1778T>C, and c.5461–1389C>A variants
showed alternative ESEs being recognized in the corresponding
mutant and the c.2160+584A>G, c.4539+1729G>T, and
c.6148−471C>T variants significantly increased the splicing scores
in different algorithms (Table S3). However, none of these six
variants showed splicing defects in HEK293T cells in the in vitro
assay (Figure S1).
3.3 | Clinical characteristics of STGD1 cases
carrying causal NCSS or deep‐intronic variants
Clinical data were collected from the corresponding patients carrying
the variants assessed in this study. The overview of the ABCA4
variants observed in trans in these patients as well as phenotypic
details are provided in Tables S1 and S2, respectively.
For all variants assessed in this study, we quantified visible
fragments from gel electrophoresis analysis to determine the
severity of variants. The quantifications observed ≤15% of WT
mRNA in four of five variants with visible WT fragments suggesting
that they represent severe variants (Table S7). For the analysis of
c.161G>A, we noted naturally occurring exon skipping for exon 3 in
14% of the WT construct. Therefore, we normalized the full‐length
fragment in mutant construct (44%) to the full‐length RNA including
exon 3 in the WT (86%). The splice defect of c.161G>A was classified
as moderately severe due to the resulting 51% (86/44 × 100)
remaining product. However, already earlier the missense variant
was proposed to be severe in STGD1 cases, and therefore we argue
that both the exon skipping and missense mutation are contributing
to the severity of this variant. Six other variants did not show any WT
fragments besides the mutant fragment and are therefore deemed
severe causal variants. Variant c.3608−7G>A did not show a splice
defect and is therefore likely not causative until proven otherwise
with another experimental setup.
Through this study, we established the splice defects for 12
ABCA4 variants found in 12 macular dystrophy probands. The
c.1938−619A>G variant is located at position +5 of the PE and
strengthened a cryptic SDS which likely led to the recognition of ESE
SC35 and SRp55 motifs. These ESEs are located in the exon–intron
boundaries and are shown to promote the recognition of exons with
weak 5′ and 3′ splice sites and are being involved in exon definition
by assisting in the recruitment of splicing factors before the removal
of the adjacent introns. Therefore, the recognition of these ESE
motifs will facilitate the splicing machinery to detect the nearby
sequence as an exon (Buvoli, Buvoli, & Leinwand, 2007; Lam &
Hertel, 2002; Wu, Zhang, & Zhang, 2005). The individual carrying this
F IGURE 3 Overview of splice defects for three deep‐intronic variants and one near exon variant. All WT and mutant midigenes were
transfected in HEK293T cells and their splicing effects were identified by RT‐PCR. The exon 5 RHO RT‐PCR was used as a control for
transfection efficiency. The chromatograms present the nucleotides identified in the mutant midigene construct. (a) Variant c.1938−619A>G
strengthened a cryptic SDS and surprisingly resulted in two independent PE insertions. Fragment 1–2 consists of a fused fragment of two PEs
encompassing 134 and 174 nt (PE1–2). PE1 (134 nt) extends from c.1937+396 to c.1937+529 and the boundaries of PE2 (174‐nt) are
c.1938−797 and c.1938−624. Fragment 2 contains the second PE of 174‐nt (PE2) only. (b) Variant c.2919−826T>A strengthened a cryptic SDS
and led to a 133‐nt PE. (c) Variant c.3050+370C>T created a new canonical SDS which resulted in a 105‐nt PE insertion. (d) The NEAR splicing
variant c.4352+61G>A enhanced a cryptic SDS’s HSF score and elongated exon 29 with 57 nt in 84% percent of the mRNA. bp, base pair;
HEK293T, human embryonic kidney 293T; HSF, human splicing factor; mRNA, messenger RNA; NEAR, near exon aberrant RNA; nt, nucleotide;
PE, pseudoexon; RT‐PCR, reverse transcription‐polymerase chain reaction; SDS, splice donor site; SSFL, SpliceSiteFinder‐like; WT, wild‐type
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variant was identified with c.5882G>A (p.Gly1961Glu) as a second
variant and was shown to segregate with the disease in the family
with a typical STGD1 phenotype (Zernant et al., 2014).
The c.2919−826T>A variant is located at the penultimate nt of
the newly recognized PE, increasing the SDS scores at the
c.2919−824 positions. The corresponding patient carries the mild
c.5882G>A (p.(Gly1961Glu)) variant on the other allele and shows
bull’s eye maculopathy, which is characteristic for STGD1 cases
carrying p.(Gly1961Glu) (Zernant et al., 2014).
4 | DISCUSSION
We found splice defects for 12 of the 19 (63%) assessed NCSS or
deep‐intronic ABCA4 variants (Figure S2). Based on the midigene
splice assays, 11 could be classified as severe variants and one
variant (c.161G>A) is considered to have a moderately severe splice
effect. The splicing effects of all tested variants and their RNA and
protein annotations were uploaded into the ABCA4 Leiden Open
(source) Variant Database (ABCA4‐LOVD). In addition, we updated
the protein outcome for those variants that were already present in
the database (www.lovd.nl/ABCA4).
Among nine NCSS variants, six variants were found to cause
skipping of one or two exons. The c.5715−5T>G variant revealed
multiple fragments due to the splice defect. All erroneous fragments
showed a 5′ elongation of exon 41, however, the variant also leads to
skipping of both exon 39 and 40 and of exon 39 only. Whereas most
NCSS variants lead to complete exon skipping, the midigene splice
assays for both c.1937+5G>A and c.6385A>G variants resulted in
partial exon deletions due to the use of cryptic splice sites within
exons 13 and 46, respectively. As observed for c.1937+5G>A, an
upstream cryptic SDS at c.1806 was utilized which led to an in‐frame
132‐nt deletion of exon 13, thereby removing amino acid residues
603–646. This affects the first extracellular domain of the ABCA4
protein, but a residual function of the protein cannot be excluded.
The prediction for the coding variant c.6385A>G was challenging
as the canonical SDS of exon 46 contains GC instead of GT, which is
recognized only by the SSFL algorithm. The SSFL values were
reduced from 91.8% to 80.3% for the mutant variant. While we
anticipated a 26‐nt exon elongation due to high predicted scores for
a cryptic splice site, or intron retention due to the small intron 46
size (73 nt), we observed the use of an upstream cryptic SDS at
position c.6340. This resulted in a 47‐nt deletion of exon 46, leading
to a frameshift resulting in a predicted truncated protein. We
hypothesize that the strong cryptic SDS at position c.6386+27 (SSFL
score: 85.3) may not be used by the splicing machinery due to the
high abundance of silencers preventing the binding of splicing factors
(Figure S3). The preferred cryptic SDS within the exon has a
relatively low SSFL score of 67.7, but the region has few predicted
silencer motifs and therefore likely is preferred over other SDSs. The
corresponding patient with a retinitis pigmentosa‐like phenotype has
the c.5461−10T>C (p.[Thr1821Aspfs*6,Thr1821Valfs*13]) patho-
genic variant as the other allele (Braun et al., 2013), which is the
most frequent severe variant in ABCA4 (Sangermano et al., 2016).
Among the 10 NEAR splice and deep‐intronic variants evaluated,
c.1938−619A>G, c.2919−826T>A, and c.3050+370C>T generated
PEs that contain stop codons and thus result in predicted truncated
ABCA4 proteins. Vaz‐Drago et al. (2017) recently showed that the
majority of deep‐intronic variants generate a canonical SAS or SDS,
while the minority creates or disrupts an ESE or ESS element. In our
study, only one (c.3050+370C>T) out of three variants introduced a
new splice site leading to a PE. Analysis of the c.1938−619A>G
variant revealed a complex effect and introduced two PEs. The
variant created a 134‐nt PE as well as a second PE of 174 nt which
TABLE 2 In vitro assessed near exon and deep‐intronic variants and the observed RNA and predicted protein effects
DNA variant RNA effect Protein effect Splice defect Variant effect
c.768+358C>T r.= p.(=) None N.A.










c.2160+584A>G r.= p.(=) None N.A.
c.2919−826T>A r.[2918_2919in-
s2919–957_2919–825,=]a
p.[Leu973Phefs*1,=]a 133‐nt PE Severe
c.3050+370C>T r.3050_3051ins3050+164_3050+368 p.(Leu1018Glufs*4) 205‐nt PE Severe
c.4352+61G>A r.[4352_4353ins4352+1_4352+57,=]a p.[Glu1452*,=]a 57‐nt exon 29
elongation
Severe
c.4539+172>T r.= p.(=) None N.A.
c.5461−1389C>A r.= p.(=) None N.A.
c.6148−471C>T r.= p.(=) None N.A.
Note: The RNA and protein effect annotations show the most abundant product followed by the less abundant RNA product observed.
Abbreviations: N. A., not applicable; nt, nucleotide; PE, pseudoexon.
aThe equal sign depicts the presence of >15% WT RNAs.
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resided 491 nt downstream. The 134‐nt PE was previously shown to
result from the c.1937+435C>G (Sangermano et al., 2019). To our
knowledge, the phenomenon of two PEs generated by a single variant
has not been described before and the underlying mechanism
remains to be elucidated.
The WT c.3050+370C residue is part of a cryptic “GC‐type” splice
site as predicted by SSFL (SSFL score: 78.9%), but apparently is not
employed by the splicing machinery. The c.3050+370C>T variant,
however, creates a canonical GT (SSFL score: 81.8%) which was
recognized by all five splice site algorithms and led as expected to a
PE insertion that contains a premature stop codon after four amino
acids p.(Leu1018Glufs*4).
Six deep‐intronic variants did not show a splicing effect, while
there were strong predictions for cryptic SDSs for the
c.2160+584A>G and c.4539−1729G>T variants. An explanation for
the absence of PEs may be a paucity of retina‐specific splicing motifs
and/or an abundance of silencer motifs (Murphy, Cieply, Carstens,
Ramamurthy, & Stoilov, 2016). Variants showing no effect on splicing
in this study may still be proven to be pathogenic when assessed in
induced Pluripotent Stem Cell (iPSC)‐derived photoreceptor pre-
cursors. For example, pathogenicity was proven when studying
ABCA4 variants c.4539+2001G>A and c.4539+2028C>T in photo-
receptor precursor cells derived from patient fibroblasts while no
effect on splicing was detected in fibroblasts of the same patients
(Albert et al., 2018). Moreover, a retina‐specific increase of a 128‐nt
PE insertion was also observed for the most frequent Leber
congenital amaurosis‐associated CEP290 variant, c.2991+1655A>G
(den Hollander et al., 2006; Dulla et al., 2018).
As current estimates indicate that NCSS, NEAR splice, and deep‐
intronic variants represent 15–20% of the causes of recessive human
diseases (Carss et al., 2017; Matlin, Clark, & Smith, 2005), we sought
to assess pathogenicity of 19 ABCA4 variants that were previously
published, or identified in our cohort. We clearly determined the
effect on splicing and, consequently, the highly likely pathogenicity
for six NCSS variants as well as three deep‐intronic variants, and
thereby contribute to a growing list of NCSS variants and the 16
pathogenic deep‐intronic variants published previously (Figure 4;
Albert et al., 2018; Bauwens et al., 2019; Braun et al., 2013;
Sangermano et al., 2019). Moreover, our study revealed a fourth
NEAR splicing variant to be pathogenic in addition to the three
previously described NEAR splice variants in ABCA4 (Bauwens et al.,
2019; Sangermano et al., 2018). An overview of the currently known
pathogenic deep‐intronic and NEAR splice variants is presented in
Figure 4.
Determining the precise effects of splice site variants will open
new opportunities for therapeutic approaches for patients carrying
these variants. As previously shown, modulation of ABCA4 pre‐mRNA
splicing can be executed through antisense oligonucleotides, which
can bind complementarily to mRNA and manipulate the splicing
process by skipping PEs (Albert et al., 2018; Bauwens et al., 2019;
Sangermano et al., 2019). Moreover, antisense oligonucleotides have
proven their effect in in vitro and in vivo studies for the most
frequent deep‐intronic variant in CEP290 that causes Leber
congenital amaurosis (Collin et al., 2012; Garanto et al., 2016). The
latter is currently in Phase II clinical trial (https://clinicaltrials.gov/
ct2/show/NCT03140969).
F IGURE 4 The landscape of all currently known pathogenic deep‐intronic and NEAR splicing variants in ABCA4. The three deep‐intronic
variants and one NEAR splicing variant deemed as pathogenic in this study are depicted in red/italic. Other variants were described elsewhere
(Albert et al., 2018; Bauwens et al., 2019; Braun et al., 2013; Sangermano et al., 2019). ABCA4, ATP‐binding cassette subfamily A member 4;
NEAR, near exon aberrant RNA
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By evaluating the pathogenic effects of putative splicing variants,
we gained crucial knowledge for evaluation of yet to be identified
NCSS, NEAR or deep‐intronic variants. While predictions by splice
site algorithms are crucial, we also observed an important, and
possibly essential, role of ESE and ESS motifs. Future studies
regarding retina‐specific splicing motifs and proteins will improve
predictions for the effect of novel NCSS and deep‐intronic variants in
ABCA4 as well as in other IRD‐associated genes.
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